Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference [Yahoo! Finance]
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Is Editas Medicine Going to $0? [Yahoo! Finance]
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401 [Yahoo! Finance]
Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]